Indonesia says to secure Sinopharm COVID-19 vaccine for private use

BPOM did not respond to a request for comment. At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity.

Reuters | Jakarta | Updated: 25-02-2021 11:07 IST | Created: 25-02-2021 11:07 IST
Indonesia says to secure Sinopharm COVID-19 vaccine for private use

Indonesia will receive at least two million doses of a coronavirus vaccine produced by China's Sinopharm for use in a private vaccination scheme due to run alongside a national inoculation programme, a minister said on Thursday. Indonesia, which has faced one of the biggest COVID-19 outbreaks in Asia, aims to vaccinate 181.5 million people within about a year using vaccines made by companies such as Sinovac Biotech, Novavax and AstraZeneca.

Luhut Binsar Pandjaitan, Indonesia's minister for maritime affairs and investment, said the China National Pharmaceutical Group (Sinopharm) vaccine would be part of the private scheme. "What's fixed is two million (doses). Three million is our hope...we will vaccinate employees in stages," he told an economic forum.

The private plan has been pushed by Indonesian business as a way for companies to buy vaccines from the government so that their employees can be vaccinated in order to help prop up the country's battered economy. The private plan is due to use alternative vaccines from the ones currently being used and the government is preparing a regulation.

Bambang Heriyanto, corporate secretary of Bio Farma, a state-owned pharmaceutical company in charge of procuring vaccines, said talks were still ongoing with Sinopharm and the vaccine needed approval from the food and drugs agency (BPOM). BPOM did not respond to a request for comment.

At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity. Sinopharm did not immediately respond to a request for comment.

Sinopharm affiliate, the Wuhan Institute Of Biological Products, said on Wednesday its vaccine had an efficacy rate of 72.51% against COVID-19, citing interim analysis of late-stage clinical trial data, without offering more details.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

East African women traders: 'Celebrating the past, planning for the future'

COVID-19 has hit women disproportionately hard across East Africa, especially those working in the informal sector. Lessons must be learnt to prevent this from happening again....

Viral variants and vaccine nationalism pose two-pronged threat to Covid victory

... ...

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

Videos

Latest News

Flight reschedules, cancellations galore as UAE India travel ban nears implementation

The UAEs decision to ban flights from India due to the worsening COVID-19 situation in the country has upset a lot of travel plans as people are making frantic efforts to reach to their destinations before the restrictions come into effect....

U.S. to double public climate finance to developing countries by 2024

The United States said on Thursday it would boost public climate finance to help poor countries reduce greenhouse gas emissions and adapt to a changing climate, doubling funding by 2024 from high average levels hit during the Obama administ...

Indonesian leader orders all-out effort to find submarine as oxygen runs low

Indonesias president ordered an all-out effort to find a missing submarine in a race against time to save the 53 crew, whose oxygen supply defence chiefs said would last only until Saturday.Indonesia sent a helicopter and five ships to sear...

Intel PC chip sales rise, but profit forecast falls short on manufacturing costs

Intel Corp on Thursday raised its annual sales outlook on booming demand for personal computers, but its second-quarter profit forecast fell short of analyst expectations as the company spends heavily to get its manufacturing operations bac...

Give Feedback